<!DOCTYPE html>
<html lang="en">
<head>        <meta charset="utf-8">
        <meta name="viewport" content="width=device-width, initial-scale=1.0">    <link
        rel="stylesheet"
        href="https://maxcdn.bootstrapcdn.com/bootstrap/4.0.0/css/bootstrap.min.css"
        integrity="sha384-Gn5384xqQ1aoWXA+058RXPxPg6fy4IWvTNh0E263XmFcJlSAwiGgFAW/dAiS6JXm"
        crossorigin="anonymous"
    />
    <link rel="stylesheet" href="https://cdnjs.cloudflare.com/ajax/libs/c3/0.6.12/c3.min.css"/>
    <style>
        h2 {
            margin-top: 35px;
        }

        html, body {
            height: 100%;
        }

        body {
            display: flex;
            flex-flow: column;
        }

        .footer {
            margin-top: auto;
            padding-top: 1em;
            background-color: #f5f5f5;
        }
    </style>    <title>OLSSON_E2F3_TARGETS_UP</title></head>

<body>
<nav class="navbar navbar-expand-lg navbar-light bg-light">
    <span class="navbar-brand">
        Molecular Signatures Database
    </span>
</nav>

<div class="container" style="margin-top: 50px; margin-bottom: 50px">
<div class="card">
        <div class="card-header">
            OLSSON_E2F3_TARGETS_UP
        </div>
        <div class="card-body">
                <p>Amplification and overexpression of the E2F3 gene at 6p22 in human bladder cancer is associated with increased tumour stage, grade and proliferation index, and in prostate cancer E2F3 overexpression is linked to tumour aggressiveness. We first used small interfering RNA technology to confirm the potential importance of E2F3 overexpression in bladder cancer development. Knockdown of E2F3 expression in bladder cells containing the 6p22 amplicon strongly reduced the extent of bromodeoxyuridine (BrdU) incorporation and the rate of cellular proliferation. In contrast, knockdown of CDKAL1/FLJ20342, another proposed oncogene, from this amplicon had no effect. Expression cDNA microarray analysis on bladder cancer cells following E2F3 knockdown was then used to identify genes regulated by E2F3, leading to the identification of known E2F3 targets such as Cyclin A and CDC2 and novel targets including pituitary tumour transforming gene 1, Polo-like kinase 1 (PLK1) and Caveolin-2. For both bladder and prostate cancer, we have proposed that E2F3 protein overexpression may cooperate with removal of the E2F inhibitor retinoblastoma tumor suppressor protein (pRB) to drive cellular proliferation. In support of this model, we found that ectopic expression of E2F3a enhanced the BrdU incorporation, a marker of cellular proliferation rate, of prostate cancer DU145 cells, which lack pRB, but had no effect on the proliferation rate of PC3 prostate cancer cells that express wild-type pRB. BrdU incorporation in PC3 cells could, however, be increased by overexpressing E2F3a in cells depleted of pRB. When taken together, these observations indicate that E2F3 levels have a critical role in modifying cellular proliferation rate in human bladder and prostate cancer.</p>
            <dl>
                <dt>Local Unique Identifier</dt>
                <dd><a href="https://bioregistry.io/msigdb:M18325">M18325</a>
                </dd>
                    <dt>
                        <span class="badge badge-primary">Relation</span>
                            in taxon (<code>RO:0002162</code>)
                    </dt>
                    <dt>
                        <ol>
                                <li><a href="https://bioregistry.io/NCBITaxon:9606">NCBITaxon:9606</a></li>
                        </ol>
                    </dt>
                    <dt>
                        <span class="badge badge-primary">Relation</span>
                            has part (<code>BFO:0000051</code>)
                    </dt>
                    <dt>
                        <ol>
                                <li><a href="https://bioregistry.io/ncbigene:5818">ncbigene:5818</a></li>
                                <li><a href="https://bioregistry.io/ncbigene:5733">ncbigene:5733</a></li>
                                <li><a href="https://bioregistry.io/ncbigene:80709">ncbigene:80709</a></li>
                                <li><a href="https://bioregistry.io/ncbigene:55968">ncbigene:55968</a></li>
                                <li><a href="https://bioregistry.io/ncbigene:10406">ncbigene:10406</a></li>
                                <li><a href="https://bioregistry.io/ncbigene:7127">ncbigene:7127</a></li>
                                <li><a href="https://bioregistry.io/ncbigene:1605">ncbigene:1605</a></li>
                                <li><a href="https://bioregistry.io/ncbigene:23293">ncbigene:23293</a></li>
                                <li><a href="https://bioregistry.io/ncbigene:91133">ncbigene:91133</a></li>
                                <li><a href="https://bioregistry.io/ncbigene:6279">ncbigene:6279</a></li>
                                <li><a href="https://bioregistry.io/ncbigene:1889">ncbigene:1889</a></li>
                                <li><a href="https://bioregistry.io/ncbigene:399665">ncbigene:399665</a></li>
                                <li><a href="https://bioregistry.io/ncbigene:840">ncbigene:840</a></li>
                                <li><a href="https://bioregistry.io/ncbigene:3910">ncbigene:3910</a></li>
                                <li><a href="https://bioregistry.io/ncbigene:771">ncbigene:771</a></li>
                                <li><a href="https://bioregistry.io/ncbigene:1999">ncbigene:1999</a></li>
                                <li><a href="https://bioregistry.io/ncbigene:378938">ncbigene:378938</a></li>
                                <li><a href="https://bioregistry.io/ncbigene:84886">ncbigene:84886</a></li>
                                <li><a href="https://bioregistry.io/ncbigene:55603">ncbigene:55603</a></li>
                                <li><a href="https://bioregistry.io/ncbigene:55268">ncbigene:55268</a></li>
                                <li><a href="https://bioregistry.io/ncbigene:871">ncbigene:871</a></li>
                                <li><a href="https://bioregistry.io/ncbigene:6364">ncbigene:6364</a></li>
                                <li><a href="https://bioregistry.io/ncbigene:9375">ncbigene:9375</a></li>
                                <li><a href="https://bioregistry.io/ncbigene:56649">ncbigene:56649</a></li>
                                <li><a href="https://bioregistry.io/ncbigene:8644">ncbigene:8644</a></li>
                        </ol>
                    </dt>
            </dl>
            <span class="badge badge-warning">Term generation via PyOBO is currently under construction</span>
            <blockquote>
                Term(reference=Reference(prefix=&#39;msigdb&#39;, identifier=&#39;M18325&#39;, name=&#39;OLSSON_E2F3_TARGETS_UP&#39;), definition=&#39;Amplification and overexpression of the E2F3 gene at 6p22 in human bladder cancer is associated with increased tumour stage, grade and proliferation index, and in prostate cancer E2F3 overexpression is linked to tumour aggressiveness. We first used small interfering RNA technology to confirm the potential importance of E2F3 overexpression in bladder cancer development. Knockdown of E2F3 expression in bladder cells containing the 6p22 amplicon strongly reduced the extent of bromodeoxyuridine (BrdU) incorporation and the rate of cellular proliferation. In contrast, knockdown of CDKAL1/FLJ20342, another proposed oncogene, from this amplicon had no effect. Expression cDNA microarray analysis on bladder cancer cells following E2F3 knockdown was then used to identify genes regulated by E2F3, leading to the identification of known E2F3 targets such as Cyclin A and CDC2 and novel targets including pituitary tumour transforming gene 1, Polo-like kinase 1 (PLK1) and Caveolin-2. For both bladder and prostate cancer, we have proposed that E2F3 protein overexpression may cooperate with removal of the E2F inhibitor retinoblastoma tumor suppressor protein (pRB) to drive cellular proliferation. In support of this model, we found that ectopic expression of E2F3a enhanced the BrdU incorporation, a marker of cellular proliferation rate, of prostate cancer DU145 cells, which lack pRB, but had no effect on the proliferation rate of PC3 prostate cancer cells that express wild-type pRB. BrdU incorporation in PC3 cells could, however, be increased by overexpressing E2F3a in cells depleted of pRB. When taken together, these observations indicate that E2F3 levels have a critical role in modifying cellular proliferation rate in human bladder and prostate cancer.&#39;, provenance=[Reference(prefix=&#39;pubmed&#39;, identifier=&#39;16909110&#39;, name=None)], relationships=defaultdict(&lt;class &#39;list&#39;&gt;, {TypeDef(reference=Reference(prefix=&#39;RO&#39;, identifier=&#39;0002162&#39;, name=&#39;in taxon&#39;), comment=None, namespace=None, definition=None, is_transitive=None, is_symmetric=None, domain=None, range=None, parents=[], xrefs=[], inverse=None, holds_over_chain=None): [Reference(prefix=&#39;NCBITaxon&#39;, identifier=&#39;9606&#39;, name=&#39;Homo sapiens&#39;)], TypeDef(reference=Reference(prefix=&#39;BFO&#39;, identifier=&#39;0000051&#39;, name=&#39;has part&#39;), comment=&#39;Inverse of part_of&#39;, namespace=None, definition=None, is_transitive=None, is_symmetric=None, domain=None, range=None, parents=[], xrefs=[], inverse=Reference(prefix=&#39;BFO&#39;, identifier=&#39;0000050&#39;, name=&#39;part of&#39;), holds_over_chain=None): [Reference(prefix=&#39;ncbigene&#39;, identifier=&#39;5818&#39;, name=None), Reference(prefix=&#39;ncbigene&#39;, identifier=&#39;5733&#39;, name=None), Reference(prefix=&#39;ncbigene&#39;, identifier=&#39;80709&#39;, name=None), Reference(prefix=&#39;ncbigene&#39;, identifier=&#39;55968&#39;, name=None), Reference(prefix=&#39;ncbigene&#39;, identifier=&#39;10406&#39;, name=None), Reference(prefix=&#39;ncbigene&#39;, identifier=&#39;7127&#39;, name=None), Reference(prefix=&#39;ncbigene&#39;, identifier=&#39;1605&#39;, name=None), Reference(prefix=&#39;ncbigene&#39;, identifier=&#39;23293&#39;, name=None), Reference(prefix=&#39;ncbigene&#39;, identifier=&#39;91133&#39;, name=None), Reference(prefix=&#39;ncbigene&#39;, identifier=&#39;6279&#39;, name=None), Reference(prefix=&#39;ncbigene&#39;, identifier=&#39;1889&#39;, name=None), Reference(prefix=&#39;ncbigene&#39;, identifier=&#39;399665&#39;, name=None), Reference(prefix=&#39;ncbigene&#39;, identifier=&#39;840&#39;, name=None), Reference(prefix=&#39;ncbigene&#39;, identifier=&#39;3910&#39;, name=None), Reference(prefix=&#39;ncbigene&#39;, identifier=&#39;771&#39;, name=None), Reference(prefix=&#39;ncbigene&#39;, identifier=&#39;1999&#39;, name=None), Reference(prefix=&#39;ncbigene&#39;, identifier=&#39;378938&#39;, name=None), Reference(prefix=&#39;ncbigene&#39;, identifier=&#39;84886&#39;, name=None), Reference(prefix=&#39;ncbigene&#39;, identifier=&#39;55603&#39;, name=None), Reference(prefix=&#39;ncbigene&#39;, identifier=&#39;55268&#39;, name=None), Reference(prefix=&#39;ncbigene&#39;, identifier=&#39;871&#39;, name=None), Reference(prefix=&#39;ncbigene&#39;, identifier=&#39;6364&#39;, name=None), Reference(prefix=&#39;ncbigene&#39;, identifier=&#39;9375&#39;, name=None), Reference(prefix=&#39;ncbigene&#39;, identifier=&#39;56649&#39;, name=None), Reference(prefix=&#39;ncbigene&#39;, identifier=&#39;8644&#39;, name=None)]}), properties=defaultdict(&lt;class &#39;list&#39;&gt;, {&#39;category_code&#39;: [&#39;C2&#39;], &#39;sub_category_code&#39;: [&#39;CGP&#39;], &#39;contributor&#39;: [&#39;Arthur Liberzon&#39;], &#39;exact_source&#39;: [&#39;Table 1&#39;]}), parents=[], synonyms=[], xrefs=[], alt_ids=[], namespace=None, is_obsolete=False)
            </blockquote>
        </div>
    </div></div>

<footer class="footer">
    <p class="small text-center text-muted">
        Generated with PyOBO
    </p>
</footer>

<script src="https://code.jquery.com/jquery-3.2.1.slim.min.js"
        integrity="sha384-KJ3o2DKtIkvYIK3UENzmM7KCkRr/rE9/Qpg6aAZGJwFDMVNA/GpGFF93hXpG5KkN"
        crossorigin="anonymous"></script>
<script src="https://maxcdn.bootstrapcdn.com/bootstrap/4.0.0/js/bootstrap.min.js"
        integrity="sha384-JZR6Spejh4U02d8jOt6vLEHfe/JQGiRRSQQxSfFWpi1MquVdAyjUar5+76PVCmYl"
        crossorigin="anonymous"></script></body>
</html>